Biogen receives EMA CHMP recommendation for ALS drug Qalsody
The EMA's decision on the marketing authorisation application for Biogen Qalsody is expected in Q2 of this year.
The EMA's decision on the marketing authorisation application for Biogen Qalsody is expected in Q2 of this year.
What's Your Reaction?
